Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets open in positive territory
Tue, 3 Feb 09:30 am

The major Asian stock markets have opened the day on a mixed note with Taiwan market (up 0.7%) and China market (up 0.4%), leading the gainers whereas Singapore market ( down 0.4%) and Hong Kong market (down 0.3%) are the major losers. The Indian markets have opened firm. Barring pharma and IT, all the sectoral indices are trading in the green with stocks from consumer durables and oil and gas being the biggest gainers.

BSE-Sensex is currently trading up by about 65 points (up 0.22%), while the NSE-Nifty is higher by about 23 points (up 0.27%). The BSE Mid Cap has opened the day in green, up by 0.44% and BSE Small Cap has opened firm, up by 0.33%. The rupee was trading at Rs 61.68 to the dollar.

Majority of the domestic pharma stocks are trading firm with Elder Pharma and Panacea Biotech being the major gainers. The proposed merger of Sun Pharmaceuticals and Ranbaxy Laboratories has come one step closer after the US Federal Trade Commission (FTC) has completed the review of the said acquisition and has granted early termination of the waiting period. The early termination of the waiting period under the Hart- Scott- Rodino Improvements Act is an important condition for the closing of the Ranbaxy acquisition. Under the consent agreement accepted by FTC, Sun Pharma and Ranbaxy will have to divest the latter's interests in generic monocycline tablets and capsules to an external third party. Sun Pharma is up 0.3% whereas Ranbaxy stock is marginally up.

Most of the FMCG stocks are trading in the green with Lakshmi Energy and Hindustan Unilever being the major gainers. As per a leading financial daily, Unilever's Chief Executive Paul Polman will be meeting the Prime Minister to discuss how its Indian subsidiary Hindustan Unilever (HUL) can participate in the social initiatives including the Swachh Bhart Mission. The Swachh Bharta Mission aims to build more than 800 m toilets and modern sewage systems to overcome problems of open defecation and open drains. Unilever has targeted to inculcate the habit of hand cleaning in nearly one billion people through Lifebuoy Handwash and provide toilet access to 25 m people through campaign for toilet cleaner Domex by the end 2015. Similarly the company's water filter brand Pureit has committed to provide 150 m litres of safe drinking water. HUL stock is presently trading up 2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open in positive territory". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.